Margarida Maia, PhD,  science writer—

Kaftrio (elexacaftor/tezacaftor/ivacaftor) — known as Trikafta in the U.S. — brings broad benefits in the form of better lung function, quality of life, and cognitive processing, while also helping to ease depression and improve stool frequency for cystic fibrosis (CF) patients, a real-world study in Italy found. For…

Loss of bladder or bowel control is common among adults with cystic fibrosis (CF), and such incontinence problems may impair patients’ quality of life and respiratory (breathing) care, regardless of the severity of their lung symptoms, a study found. “Persistent coughing” — a common symptom in cystic fibrosis —…

An MRI technique revealed signs of reversible bronchiectasis (widened and inflamed airways) in more than one in three people with cystic fibrosis (CF) being treated with Kaftrio, sold as Trikafta in the U.S., as part of a small one-year study in France. The technique, called ultrashort echo-time MRI, is…

Six months of treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), sold as Trikafta in the U.S., leads to increases in body mass index (BMI) and fat mass in people with cystic fibrosis (CF), a small study has found. However, while BMI increased for both men and women, only women showed a…

One month of treatment with Trikafta, a triple combo of elexacaftor, tezacaftor, and ivacaftor, helped to clear mucus from the airways of adolescents and adults with cystic fibrosis (CF), a study found. Mucus became less thick, which may have helped in preventing its buildup in the airways, increasing…

Trikafta, a combination of elexacaftor, tezacaftor, and ivacaftor, lowered the number of Pseudomonas aeruginosa bacteria in the nose and sinuses of people with cystic fibrosis (CF) taking part in a small study. Mucus from the sinuses — air-filled pockets in the skull — can enter the lungs, so…

Parents of adolescents and young adults with cystic fibrosis (CF) retain a sense of responsibility for their children as they transition into adult healthcare services, and they can be frustrated by the changes demanded, an interview study reported. Healthcare providers should recognize the evolving roles of both patients and…

The Cystic Fibrosis (CF) Foundation is giving up to $9 million in additional support to advance clinical testing of ARCT-032, a messenger RNA therapy with the potential to benefit anyone with CF, regardless of their disease-causing mutation. Arcturus Therapeutics, the inhalation therapy’s developer, is using the funding…

People with cystic fibrosis (CF) in the U.S. tend to live more than a decade longer now than patients did about 20 years ago, according to a study that found deaths from CF have about halved from 1999 to 2020. “These changes were relatively slow during an earlier period…

BX004, a virus-based cocktail designed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), can reduce the number of bacteria in the lungs with no signs of resistance to treatment over time, a study has found. Findings from the first part of a small Phase 1b/2a…